Definium Therapeutics (DFTX) Assets Average (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Assets Average data on file, last reported at $420.7 million in Q1 2026.

• Quarterly Assets Average rose 45.7% year-over-year to $420.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $420.7 million (up 45.7% YoY) and the FY2025 annual result came in at $371.1 million, up 73.95% from the prior year.
• Assets Average improved to $420.7 million in Q1 2026 per DFTX's latest filing, from $338.5 million in the prior quarter.
• Across five years, Assets Average topped out at $420.7 million in Q1 2026 and bottomed at $133.0 million in Q4 2023.
• The 5-year median for Assets Average is $200.0 million (2024), against an average of $227.3 million.
• The widest annual swing landed in 2022, when Assets Average retreated 28.16%; it then jumped 133.72% in 2024.
• Tracing DFTX's Assets Average over 5 years: stood at $175.4 million in 2022, then retreated by 24.17% to $133.0 million in 2023, then jumped by 133.72% to $311.0 million in 2024, then advanced by 8.86% to $338.5 million in 2025, then climbed by 24.28% to $420.7 million in 2026.
• Per Business Quant, the three latest DFTX Assets Average figures stand at $420.7 million (Q1 2026), $338.5 million (Q4 2025), and $251.0 million (Q3 2025).

Peer Comparison